Biogen Pharmachem Industries Past Earnings Performance
Past criteria checks 2/6
Biogen Pharmachem Industries has been growing earnings at an average annual rate of 48.5%, while the Capital Markets industry saw earnings growing at 28% annually. Revenues have been growing at an average rate of 10.5% per year. Biogen Pharmachem Industries's return on equity is 2.4%, and it has net margins of 88.8%.
Key information
48.5%
Earnings growth rate
76.7%
EPS growth rate
Capital Markets Industry Growth | 20.7% |
Revenue growth rate | 10.5% |
Return on equity | 2.4% |
Net Margin | 88.8% |
Next Earnings Update | 13 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biogen Pharmachem Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 15 | 14 | 0 | 0 |
31 Mar 24 | 8 | 19 | 1 | 0 |
31 Dec 23 | 10 | 10 | 2 | 0 |
30 Sep 23 | 12 | 12 | 2 | 0 |
30 Jun 23 | 25 | 25 | 2 | 0 |
31 Mar 23 | 3 | 5 | 2 | 0 |
31 Dec 22 | 10 | 4 | 0 | 0 |
30 Sep 22 | 7 | 1 | 0 | 0 |
30 Jun 22 | -3 | -18 | 1 | 0 |
31 Mar 22 | 25 | 0 | 1 | 0 |
31 Dec 21 | 61 | 8 | 0 | 0 |
30 Sep 21 | 39 | -14 | 0 | 0 |
30 Jun 21 | 29 | -14 | 0 | 0 |
31 Mar 21 | 16 | -16 | 0 | 0 |
31 Dec 20 | 0 | -23 | 0 | 0 |
30 Sep 20 | 0 | -1 | 0 | 0 |
30 Jun 20 | 0 | -1 | 0 | 0 |
31 Mar 20 | 0 | -1 | 0 | 0 |
31 Dec 19 | 5 | 0 | 0 | 0 |
30 Sep 19 | 9 | 0 | 0 | 0 |
30 Jun 19 | 9 | 0 | 0 | 0 |
31 Mar 19 | 9 | 0 | 0 | 0 |
31 Dec 18 | 5 | -65 | 0 | 0 |
30 Sep 18 | 0 | -66 | 0 | 0 |
30 Jun 18 | 0 | -67 | 0 | 0 |
31 Mar 18 | 0 | -66 | 0 | 0 |
31 Dec 17 | 0 | -1 | 1 | 0 |
30 Sep 17 | 0 | -1 | 1 | 0 |
30 Jun 17 | 0 | -1 | 1 | 0 |
31 Mar 17 | 0 | -1 | 0 | 0 |
31 Dec 16 | 0 | 0 | 0 | 0 |
30 Sep 16 | 0 | 0 | 0 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
31 Mar 16 | 0 | 0 | 0 | 0 |
31 Dec 15 | 0 | -1 | 0 | 0 |
30 Sep 15 | 0 | -1 | 0 | 0 |
30 Jun 15 | 0 | -1 | 0 | 0 |
31 Mar 15 | 0 | -1 | 0 | 0 |
31 Dec 14 | 0 | -1 | 0 | 0 |
30 Sep 14 | 0 | -1 | 0 | 0 |
30 Jun 14 | 0 | -1 | 0 | 0 |
31 Mar 14 | 0 | -1 | 0 | 0 |
Quality Earnings: 531752 has high quality earnings.
Growing Profit Margin: 531752's current net profit margins (88.8%) are lower than last year (96.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531752 has become profitable over the past 5 years, growing earnings by 48.5% per year.
Accelerating Growth: 531752's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 531752 had negative earnings growth (-44.3%) over the past year, making it difficult to compare to the Capital Markets industry average (64%).
Return on Equity
High ROE: 531752's Return on Equity (2.4%) is considered low.